Page 154 - Revol6

Evaluación de la Salud Física y el Estilo de Vida en las Personas con Trastorno Mental Grave
75. Kato MM, Currier MB, Gómez CM, Hall L, González-Blanco M.
Prevalence of Metabolic Syndrome in Hispanic and Non-
Hispanic Patients With Schizophrenia. Prim Care Companion J
Clin Psychiatry. 2004; 6 (2): 74-7.
76. Kato MM, Currier MB, Villaverde O, Gónzalez-Blanco M. The
relation between body fat distribution and cardiovascular risk fac-
tors in patients with schizophrenia: a cross-sectional pilot study.
Prim Care Companion J Clin Psychiatry. 2005; 7 (3):115-20.
77. Koran LM, Sox HC Jr, Marton KI, Moltzen S, Sox CH, Kraemer
HC, Imai K, Kelsey TG, Rose TG Jr, Levin LC, et al. Medical
evaluation of psychiatric patients. I. Results in a state mental
health system. Arch Gen Psychiatry. 1989; 46 (8): 733-40.
78. Koranyi EK. Morbidity and rate of undiagnosed physical illnes-
ses in a psychiatric clinic population. Arch Gen Psychiatry. 1979;
36 (4): 414-9.
79. Lambert T, Velakoulis D, Pantelis C. Medical comorbidity in
schizophrenia. Med J Aust. 2003; 178 (9) Suppl 5: 67-70.
80. Laties AM, Dev VJ, Geller W, Rak I, Brecher M, Nasrallah H:
Safety update on lenticular opacities: benign experience with
620.000 US patient exposures to quetiapine, in Proceedings of
the 39th Annual Meeting of the American College of
Neuropsychopharmacology. Nashville, Tenn, ACNP, 2000, Pag
354.
81. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist
J. Incidence of cancer among persons with schizophrenia and
their relatives. Arch Gen Psychiatry. 2001; 58 (6): 573-8.
82. Lieberman AA, Coburn AF. The health of the chronically men-
tally ill: a review of the literature. Community Ment Health J
1986; 22: 104-16.
83. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The
UKU side effect rating scale. A new comprehensive rating scale
for psychotropic drugs and cross-sectional study of side effects in
neuroleptic-treated patients. Aca Psychiatr Scand. 1987; 37 (86)
suppl: 1-100.
84. Lipper S, Werman DS. Schizophrenia and intercurrent physical
illness: a critical review of the literature. Compr Psychiatry.
1977; 18 (1):11-22.
85. Llorca PM, Chereau I, Bayle FJ y cols; Tardive dyskinesias and
antipsychotics: a review. Eur Psychiatry 2002; 17: 129-138.
86. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE,
Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N,
Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-
Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ,
Davis B, Shon S. Physical health monitoring of patients with
schizophrenia. Am J Psychiatry. 2004; 161(8): 1334– 49.
87. Masterson E, O`Shea B. Smoking and malignancy in schizophre-
nia. Br J Psychiatry 1984; 145: 429-32.
88. McCreadie RG. Diet, smoking and cardiovascular risk in people
with schizophrenia: descriptive study Br J Psychiatry 2003; 183:
534-39.
89. McCreadie RG, Stevens H, Henderson J et al. The dental health
of people with schizophrenia. Acta Psychiatr Scand. 2004; 110
(4): 306-10.
90. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM,
Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA.
Prevalence of the metabolic syndrome in patients with schizoph-
renia: Baseline results from the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) schizophrenia trial and com-
parison with national estimates from NHANES III. Schizophr
Res. 2005; 80 (1): 19-32.
91. McKinnon K, Cournos F, Meyer-Bahlburg HF, Guido JR,
Caraballo LR, Margoshes ES, Herman R, Gruen RS, Exner TM.
Reliability of sexual risk behavior interviews with psychiatric
patients. Am J Psychiatry. 1993 Jun;150(6):972-4.
92. Mendez MF, Grau R, Doss RC, Taylor JL. Schizophrenia in epi-
lepsy: seizure and psychosis variables. Neurology. 1993; 43 (6):
1073-7.
93. Meyer JM. Enfermedad cardiovascular e hiperlipidemia en
pacientes con esquizofrenia. En: Meyer JM y Nasrallah H (eds).
Efermedades medicas y esquizofrenia. Ars Medica. Barcelona,
2004: 55-77.
94. Meyer JM, Koro CE. The effects of antipsychotic therapy on
serum lipids: a comprehensive review. Schizophr Res. 2004; 70
(1): 1-17.
95. Miyaoka T, Seno H, Itoga M, Iijima M, Inagaki T, Horiguchi J.
Schizophrenia-associated idiopathic unconjugated hyperbilirubi-
nemia (Gilbert’s syndrome). Clin Psychiatry. 2000; 61(11): 868-
71.
96. Mortensen PB. Neuroleptic medication and reduced risk of pros-
tate cancer in schizophrenic patients. Acta Psychiatr Scand;
1992; 85: 390-3.
97. Mortensen PB .Mortality and physical illnes in schizophrenia.
En: Murray RM, Jones PB, Susser E, et al (eds). The
Epidemiology of Schizophrenia. Cambridge, Mass: University
Press; 2003. Pág: 275-287.
98. Mortensen PB and Juel K. Mortality and causes of death in first
admitted schizophrenic patients. Br J Psychiatry 1993; 163:
183-9.
99. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee
K, Morrison RL, Yadalam KG. Prevalence of substance abuse in
schizophrenia: demographic and clinical correlates. Schizophr
Bull. 1990; 16(1): 31-56.
100. Muir-Cochrane E. Medical co-morbidity risk factors and
barriers to care for people with schizophrenia. J Psychiatr Ment
Health Nurs. 2006 Aug;13 (4): 447-52.
101. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL.
Diabetes mellitus in schizophrenic patients. Compr Psychiatry.
1996; 37 (1): 68-73.
102. Nasrallah HA. An Overview of Common Medical
Comorbidities in Patients With Schizophrenia. J Clin
Psychiatry. 2005; 66 (Supplement 6): 3-4.
103. Nasrallah HA. Neurologic comorbidities in schizophrenia. J
Clin Psychiatry. 2005b; 66 (Suppl 6): 34-46.
104. Newcomer JW. Metabolic considerations in the use of antipsy-
chotic medications: a review of recent evidence. J Clin
Psychiatry. 2007;68 Suppl 1:20-7.
105. Newcomer JW. Abnormalities of glucose metabolism associated
with atypical antipsychotic drugs. J Clin Psychiatry. 2004; 65
Suppl 18: 36-46.
106. Newcomer JW. Medical risk in patients with bipolar disorders
and schizophrenia. J Clin Psychiatry. 2006; 67 Suppl 9: 25-30.
107. Newman SC and Bland RC. Mortality in a cohort of patients
with schizophrenia: a record linkage study. Canadian Journal of
Psychiatry, 1991; 36: 224-39.
108. Ortega JM, Gurpegui M, Díaz FJ, De León J. Tabaco y esqui-
zofrenia. Adicciones. 2004. Vol. 16, Supl 2: 177-190.
109. Ortega A, Micó JA, González A. Efectos endocrinos de los
antipsicóticos. Actas Esp de Psiquiatr 2001; 29 (Supl.1): 36-45.
110. Ösby U, Correia N, Brandt L, Ekbom A, Sparén P. Time trends
in schizophrenia mortality in Stockholm County, Sweden:
cohort study. BMJ 2000a; 321: 483-4.
111. Ösby U, Correia N, Brandt L, et al. Mortality and causes of
death in schizophrenia in Stockholm county, Sweden. Schizophr
Res. 2000b; 45 (1-2): 21-8.
112. Peet M. Diet, diabetes and schizophrenia: review and hypothe-
sis. Br J Psychiatry Suppl. 2004; 47: 102-5.
113. Perry PJ, Miller DD, Arndt SV, Smith DA, Holman TL.
Haloperidol dosing requirements: the contribution of smoking
and nonlinear pharmacokinetics. J Clin Psychopharmacol.
1993; 13 (1): 46-51.
114. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL,
Goodwin FK. Comorbidity of mental disorders with alcohol
and other drug abuse. Results from the Epidemiologic
Catchment Area (ECA) Study. JAMA. 1990; 264 (19): 2511-8.
115. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock
SM, Butterfield MI et al. Prevalence of HIV, hepatitis B, and
hepatitis C in people with severe mental illness. Am J Public
Health. 2001; 91 (1): 31-7.
116. Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J,
Drummer OH, Palmer S, Browne C, Wallace C. Sudden death in
psychiatric patients. Br J Psychiatry. 1998; 172: 331-6.
117. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tole-
rance in first-episode, drug-naive patients with schizophrenia.
Am J Psychiatry. 2003; 160(2): 284-9.
118. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The
effects of atypical antipsychotics on visceral fat distribution in
first episode, drug-naive patients with schizophrenia. Life Sci.
2004; 74 (16): 1999-2008.
Evaluación en Rehabilitación Psicosocial 161